Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
Cytokinetics states that its New Drug Application for aficamten in obstructive hypertrophic cardiomyopathy is under ongoing regulatory review, and that timing of any approval, final labeling, and the need for a REMS program or other limitations remain uncertain. The company highlights that such regulatory outcomes could affect the commercial prospects for aficamten and could also influence its ability to draw funds under an existing Loan Agreement if conditions are not met. The filing reiterates these are forward-looking statements that speak only as of the report date and that the company may not update them except as required by law.
Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics Inc. (CYTK), reported transactions dated 09/09/2025 under a Rule 10b5-1 plan. He exercised 2,000 non‑qualified stock options at a $10.60 exercise price and acquired 2,000 shares, and concurrently sold 2,000 shares at $51.29. After these transactions he beneficially owns 140,610 shares.
Cytokinetics, Incorporated filed an amended current report to correct a missing hyperlink to a press release about new data for its drug candidate aficamten. The press release covers additional aficamten results presented at the European Society of Cardiology Congress 2025 in Madrid.
The data include a pre-specified analysis from the MAPLE-HCM study on how aficamten affects heart structure and function, published in the Journal of the American College of Cardiology, and a Late Breaking Clinical Science presentation on atrial fibrillation incidence and impact associated with aficamten, published in Heart Rhythm.
Cytokinetics, Incorporated filed a report to highlight a key clinical milestone. The company announced that the primary results from its MAPLE-HCM study, which compares metoprolol with aficamten in patients with left ventricular outflow tract (LVOT) obstruction and hypertrophic cardiomyopathy (HCM), were presented in a Hot Line Session at the European Society of Cardiology Congress 2025 in Madrid, Spain. At the same time, these results were published in The New England Journal of Medicine, underscoring the scientific importance of the data. A full press release describing this announcement is included as Exhibit 99.1, giving more detail on the study and its findings.
Dr. Edward M. Kaye, a director of Cytokinetics Inc. (CYTK), reported a sale of 6,756 shares of the issuer's common stock on 09/02/2025 at a reported price of $50 per share, leaving him with 23,230 shares beneficially owned following the transaction. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
Cytokinetics, Inc. (CYTK) filed a Form 144 notifying a proposed sale of 4,300 common shares, estimated at an aggregate market value of $151,919.00, to be executed approximately on 09/02/2025 on NASDAQ. The securities were acquired as restricted stock units (RSUs) on 01/02/2024 and the filing indicates the broker handling the transaction is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states there were 119,657,156 shares outstanding for the class reported. No securities of the issuer were reported sold by the reporting person in the prior three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Insider sale reported: Director Robert A. Harrington sold 2,150 shares of Cytokinetics, Inc. (CYTK) on 09/02/2025 at $48.67 per share, reducing his direct holdings to 20,493 shares. The Form 4 indicates the sale was reported under a transaction code for a sale and the filing was signed by an attorney-in-fact. The form also marks a box indicating the transaction may have been made pursuant to a written plan.
Robert I. Blum, President & CEO and a director of Cytokinetics, Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 09/02/2025 at a reported price of $48.76 per share. After the transaction, Mr. Blum is shown as beneficially owning 378,108 shares directly and additionally reports indirect beneficial ownership of 2,083 shares held by each of two irrevocable trusts (The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust). The Form 4 was signed by an attorney-in-fact for Mr. Blum.
Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.
Cytokinetics Inc. (CYTK) reports a non-derivative equity award to director James M. Daly. On 08/19/2025 Mr. Daly received a non-qualified stock option to purchase 27,450 shares of common stock with an exercise price of $37.84 per share. The option becomes exercisable on 09/19/2025 and expires on 08/19/2035. Following the reported transaction, Mr. Daly beneficially owns 27,450 shares underlying the option as a direct position. The filing states this was an initial grant to a new director.